Invesco Ltd. Sells 51,731 Shares of Envista Holdings Co. (NYSE:NVST)

Invesco Ltd. cut its holdings in Envista Holdings Co. (NYSE:NVST - Free Report) by 13.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 343,139 shares of the company's stock after selling 51,731 shares during the quarter. Invesco Ltd. owned about 0.20% of Envista worth $6,619,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in NVST. Venturi Wealth Management LLC increased its position in shares of Envista by 528.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after buying an additional 1,638 shares in the last quarter. GAMMA Investing LLC increased its stake in Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock valued at $44,000 after buying an additional 538 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Envista during the fourth quarter worth about $53,000. Mitsubishi UFJ Trust & Banking Corp bought a new position in shares of Envista in the fourth quarter valued at $86,000. Finally, KBC Group NV raised its stake in Envista by 63.9% in the fourth quarter. KBC Group NV now owns 7,903 shares of the company's stock valued at $152,000 after buying an additional 3,082 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. UBS Group lowered their target price on Envista from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Monday, March 10th. Morgan Stanley set a $16.00 price objective on Envista in a research note on Tuesday, April 15th. Wells Fargo & Company set a $19.00 target price on Envista in a research note on Saturday, March 8th. JPMorgan Chase & Co. lowered their price target on shares of Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Finally, New Street Research set a $19.00 price objective on shares of Envista in a research note on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $20.18.

Envista Stock Up 2.8 %

Envista stock traded up $0.45 on Thursday, hitting $16.53. 809,159 shares of the stock traded hands, compared to its average volume of 2,512,093. The business's fifty day simple moving average is $16.90 and its 200 day simple moving average is $19.06. The firm has a market cap of $2.80 billion, a P/E ratio of -2.54, a price-to-earnings-growth ratio of 1.27 and a beta of 1.12. Envista Holdings Co. has a 1 year low of $14.22 and a 1 year high of $23.00. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, sell-side analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.